News: Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

6:11am EDT
Price Change (% chg)

Rs3.45 (+0.48%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Search Stocks
Select another date:

Fri, Jun 27 2014

Indian shares edge higher; defensives surge

* BSE index gains 0.15 pct; NSE ends 0.21 pct higher * Century Textile rallies after investor Damani buys stake * Aban likely to launch up to $150 mln share sale on Friday - sources * Ranbaxy gets FDA approval for Novartis's Diovan generic By Abhishek Vishnoi MUMBAI, June 27 - Indian shares rose on Friday as defensive stocks such as Sun Pharmaceutical Industries and Ranbaxy Laboratories jumped on the U.S. regulator's approval for a key drug while IT stocks gained

UPDATE 1-India's Ranbaxy posts loss after write-offs on US import bans

* Compares with analysts' forecast for 958.7 mln in profit

India's Ranbaxy posts March-quarter loss on write-offs

MUMBAI, May 9 - Indian drugmaker Ranbaxy Laboratories Ltd, which has agreed to be acquired by rival Sun Pharmaceutical Industries Ltd for $3.2 billion, posted a surprise loss in the March quarter due to write-offs related to regulatory sanctions for poor manufacturing quality.

UPDATE 1-Market Chatter-Corporate finance press digest

(Adds item on Freshpet LLC, El Pollo Loco Inc, Sun Pharmaceutical Industries Ltd, Go Daddy Group)

India's Sun Pharma plans gradual phase-out of Ranbaxy-branded drugs in U.S.: sources

MUMBAI - India's Sun Pharmaceutical Industries Ltd plans to begin phasing out sales of generic drugs branded as Ranbaxy Laboratories Ltd products in the United States, after completing a $3.2 billion takeover of its loss-making rival by the year end, sources with direct knowledge of the matter said.

Update-Moody's: Daiichi Sankyo Will Benefit from Sun Pharma's Acquisition of Ranbaxy

Sun Pharmaceutical Industries Ltd (Sun Pharma) & Ranbaxy Laboratories Ltd (Ranbaxy)

Deals of the day- Mergers and acquisitions

April 7 - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

CORRECTED-India's Sun Pharma expects Ranbaxy business to be profitable in short term

(Corrects first and last paragraphs to say Dilip Shanghvi is managing director, not chairman of Sun Pharma)

India's Ranbaxy slumps, Sun Pharma surges on $3.2-billion acquisition

MUMBAI - Shares in India's Ranbaxy Laboratories Ltd fell as much as 3.2 percent on profit-taking after Sun Pharmaceutical Industries Ltd said it will buy the company in a $3.2 billion all-share deal, creating the world's fifth-largest generic drug maker.

UPDATE 1-Indian shares inch higher, not far from record highs

* Metal stocks continue to fall (Updates with consumer price inflation data)

Select another date:
Search Stocks